PDS Biotechnology Corporation

54 articles with PDS Biotechnology Corporation

• PDS Biotechnology Announces Participation in Noble Capital Markets Virtual Road Show Series

  10/1/2020

  PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune ® T-cell activating technology, today announced their participation in Noble Capital Markets’ Virtual Road Show Series, presented by Channelchek, scheduled for October 6, 2020. The virtual road show will feature a corporate presentation from PDS

• PDS Biotechnology to Present Results from its Phase 1 Trial of PDS0101 and the Phase 2 Clinical Strategy in Patients with Advanced HPV-Associated Malignancies

  9/28/2020

  PDS Biotechnology Corporation (“PDS Biotech” or the “Company”) (Nasdaq: PDSB), today announced that its Chief Medical Officer, Lauren V. Wood, M.D. will present key data from the company’s previously reported Phase 1 trial of PDS0101

• PDS Biotechnology to Participate in Upcoming Healthcare Investor Conferences - Sep 08, 2020

  9/8/2020

  PDS Biotechnology Corporation, a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology, announced that Frank Bedu-Addo, CEO of PDS Biotech, will present virtually at the H.C. Wainwright & Co.

• PDS Biotechnology Announces Participation in Noble Capital Markets C-Suite Interview Series

  8/31/2020

  PDS Biotechnology Corporation (NASDAQ: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology, today announced its participation in Noble Capital Markets’ C-Suite Interview Series, presented by Channelchek. 

• PDS Biotechnology Reports Financial Results for the Second Quarter 2020 and Provides Business Update

  8/13/2020

  PDS Biotechnology Corporation, a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology, announced its financial results for the second quarter ended June 30, 2020 and provided a business update.

• PDS Biotechnology Corporation Announces Closing of Approx. $19 Million Public Offering and Full Exercise of Underwriter's Option to Purchase Additional Shares

  8/13/2020

  PDS Biotechnology Corporation (Nasdaq: PDSB) ("PDS Biotechnology" or the "Company"), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology

• PDS Biotechnology Corporation Announces Pricing of $16.5 Million Public Offering of Common Stock

  8/11/2020

  PDS Biotechnology Corporation (“PDS Biotech” or the “Company”) (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune ® T-cell activating technology, today announced the pricing of its previously announced underwritten public offering consisting of 6,000,000 shares of common stock at a public offering price of $2.75 per share. The

• PDS Biotechnology Corporation Announces Proposed Public Offering of Common Stock

  8/10/2020

  PDS Biotechnology Corporation (“PDS Biotech” or the “Company”) (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology,

• PDS Biotechnology Announces Conference Call and Webcast for Second Quarter 2020 Financial Results

  7/30/2020

  PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune ® T-cell activating technology, today announced that the Company will report financial results for the second quarter ended June 30, 2020 on Thursday, August 13, 2020, before the market opens. Following the release, Dr. Frank Bedu-Addo, Chief Exec

• PDS Biotech Announces Preclinical Data for PDS0203, a T-Cell Activating Recombinant Protein Vaccine Against COVID-19

  7/27/2020

  Versamune-CoV-2 (PDS0203) generated high levels of robust, long-lasting CD8 (killer) T-cell responses and potent neutralizing antibody responses within 14 days of vaccination

• PDS Biotech Collaborator Granted NIAID Award to Accelerate Development of Versamune®-Based Universal Influenza Vaccine

  7/14/2020

  PDS Biotech ramps up third infectious disease vaccine program, PDS0202 for influenza, following PDS0201 for tuberculosis and PDS0203 for COVID-19

• PDS Biotech Announces Publication of Preclinical Results of PDS0101 Combination by the National Cancer Institute in the Journal for ImmunoTherapy of CancerNCI-led Phase 2 clinical trial of this reported combination was initiated in June 2020

  6/22/2020

  PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune ® T-cell activating technology, today announced the publication of data generated by the National Cancer Institute (NCI) based on preclinical studies of PDS Biotech’s lead clinical program, PDS0101, in combination with two other investigational an

• PDS Biotechnology and Farmacore Biotechnology Announce Co-Development of PDS0204 COVID-19 Vaccine

  6/17/2020

  Brazilian government to provide initial funding support to progress development of Versamune ® -based vaccine to prevent COVID-19 infection FLORHAM PARK, N.J., June 17, 2020 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune ® T-cell activating technology, today announced a co-development agreement with Farmacore Biotechnology fo

• PDS Biotech Announces Initiation of Phase 2 Trial of PDS0101 Led by the National Cancer Institute

  6/15/2020

  PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune ® T-cell activating technology, today announced that the first patient has been dosed in the National Cancer Institute’s (NCI) Phase 2 clinical study of PDS0101 in the treatment of advanced human papillomavirus (HPV) associated cancers. This clini

• PDS Biotech Announces Clinical Trial of Its Lead Immunotherapy Product, PDS0101, in Combination with Chemoradiotherapy in Advanced Cervical Cancer

  6/4/2020

  PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology, today announced a Phase 2 clinical trial to evaluate its lead immunotherapy product, PDS0101,

• PDS Biotechnology to Present at the 2020 Virtual Investor Summit

  6/2/2020

  PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune ® T-cell activating technology, today announced that Dr. Frank Bedu-Addo, President and Chief Executive Officer, is scheduled to present  at the 2020 Virtual Investor Summit being held on June 9-12, 2020. Details of the presentation are as follo

• PDS Biotechnology Reports Financial Results for the First Quarter 2020 and Provides Business Update

  5/13/2020

  PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology, today announced its financial results for the first quarter ended March 31, 2020 and provided a business update. First Quarter 2020 and Recent Business Highlights Initiated novel vaccine development programs for

• PDS Biotechnology Announces Publication at American Society of Clinical Oncology (ASCO) 2020

  5/13/2020

  PDS Biotechnology Corporation announced the publication of its abstract on preclinical studies of PDS0102 at the American Society of Clinical Oncology Virtual Scientific Program being held May 29-31, 2020.

• PDS Biotechnology Announces Conference Call and Webcast for First Quarter 2020 Financial Results

  5/4/2020

  PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology, today announced that the Company will release financial results for the first quarter ended March 31, 2020 on Wednesday, May 13, 2020, before the market opens. Following the release, Dr. Frank Bedu-Addo, Chief Executiv

• PDS Biotechnology Expands CRADA with the National Cancer Institute to Include Second Versamune®-Based Anti-Cancer Product

  4/29/2020

  NCI to study PDS0103, in addition to planned Phase 2 clinical evaluation of PDS0101 in combination with other therapeutic agents